Strategy planning of jhonson &jhonson

Strategic Planning
Johnson & Johnson remains a broadly based health care company, one that is in a
truly unique position capture and develop opportunities that will help people
around the world. Across our pharmaceutical, biologics, devices, diagnostics and
consumer businesses, we have the know-how to bring completely new - and
needed - health care solutions to market.
This fundamental strategic direction is set by our Management Team with advice
and support of the Board of Directors and implemented locally at over 275
operating companies located in 60 countries throughout the world. With some
exceptions, each of our companies is managed by citizens of the country where it is
located.
We are organized on the principle of decentralized management. Senior
management groups at each operating company are responsible for their own
strategic plans. In developing these plans, our people worldwide are guided by and
united in carrying out the ethical principles and responsibilities outlined in Our
Credo.
Our Management Team meets throughout each year with our Board members to
discuss strategic direction and major developments of the Company's various
businesses. This interactive, on-going dialogue provides our Directors with insight
into the activities and direction of the Company's business.
Guidelines Relative to Regulation Fair Disclosure

Authorized Spokespersons

Investment Community The following individuals are authorized to

communicate with the investment community (including analysts, stockbrokers,

individual and institutional shareholders but excluding the media and rating
agencies):
Chairman/CEO
Vice Chairman
Vice President, Finance/CFO
Corporate Treasurer
Vice President, Investor Relations
Director, Investor Relations
Corporate Secretary
Assistant Corporate Secretary
For purposes of these Guidelines, these individuals are referred to as "Authorized
Investment Community Contacts."
End of Quarter Communications and Meetings

1. Quiet Period The period beginning two weeks prior to the end of the quarter
and ending the day before the quarter-end date should be observed as a quiet period
with no general business discussions by management with analysts or investors.
However, during the quiet period, the Investor Relations Department may provide
answers to fact-based inquiries from analysts or investors.
2. Silent Period The period beginning on the quarter-end date and ending at the
time of the earnings release for that quarter should be observed as a silent period
with no formal or informal business discussions by management with analysts or
investors and no answers provided to inquiries (even fact-based) from analysts or
investors. Exceptions may occur at the Company's discretion based on need to
discuss breaking news or otherwise.
3. Analyst Meetings/Conference Calls All analyst meetings/conference calls to
discuss quarterly and annual financial and business information should be

simultaneously broadcast over the internet and/or via telephone conference call to
all interested members of the public. Appropriate advance notice of the meeting,
and the simultaneous broadcast, should be made in a press release or other method
of communication in compliance with Regulation FD.
4. Earnings Press Release Earnings Press Releases will be released to PR
Newswire, furnished to the SEC on a Form 8-K, and posted on the Corporate
Website at or prior to the commencement of meeting/call as determined by Investor
Relations and the Chief Financial Officer and in compliance with applicable SEC
and NYSE rules.
5. Guidance, relative to the First Call EPS range for an annual period, may be
provided in the Earnings Press Release and modifications to guidance may be
provided in each quarter in the Earnings Press Release, if necessary. Generally, the
Company will not update this guidance or provide additional guidance during the
quarter, except as deemed necessary by the Vice President, Finance/CFO, and then
only in a public forum in accordance with Regulation FD.
Communications with Analysts

1. Review of Analyst Draft Reports When asked to review analyst draft reports,
the Investor Relations Department should limit review and comment to the
following:
(a) Correcting historical factual information only.
(b) Pointing out information that is in the public domain,
(c) Providing non-public information the company believes is clearly not material.
(d) Discussing generally the factors that might influence the underlying
assumptions used for future projections.
(e) Not embracing or commenting on long-term projections or conclusions.
2. Review of Earnings Models The Investor Relations Department should not
review earnings models.
3. Analyst Meetings/Conference Calls All analyst meetings/conference calls (to
discuss other than quarterly and annual financial and business information) should
be simultaneously broadcast over the internet or via telephone conference call to
all interested members of the public. Appropriate advance notice of the meeting

and the simultaneous broadcast, in light of the communication, should be made in a

press release or other method of communication in compliance with Regulation
FD.
Pharmaceutical and Medical Devices Product Pipeline
Information

The following information regarding the pipeline of new drugs (including line
extensions) and medical devices may be disclosed:
Chemical or device name
Brand name (if available)
Indication
Patent expiration date
Clinical stage (if appropriate)
Mechanism of action
Market size/market factors
Previously published clinical trial data
Specific projected regulatory filing dates or estimated approval dates for any
products, regardless of stage, should not be disclosed (except that general timing,
such as year or quarter, for select new molecular entities may be appropriate to
disclose). For Pharmaceuticals, the Company's policy is generally to highlight only
those products that are in Phase III clinical and beyond. Products in Phase II
clinical stage and earlier are generally higher risk and typically many years from
the marketplace and generally should not be discussed. Public disclosure related to
the Pipeline will take place at key points in the development process (e.g., entering
Phase III or a regulatory filing) and will be made in compliance with Regulation
FD.
Company Overview

Johnson & Johnson's commitment to innovative health care products has resulted
in consistent financial performance. The Company has 31 consecutive years of
adjusted earnings increases and 53 consecutive years of dividend increases.
Johnson & Johnson, through its family of companies, employs approximately
127,000 people worldwide and is engaged in the research and development,
manufacture and sale of a broad range of products in the health care field in
virtually all countries of the world. Johnson & Johnson's primary interest, both
historically and currently, has been in products related to human health and wellbeing. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
Johnson & Johnson is organized on the principle of decentralized management.
The Executive Committee of Johnson & Johnson is the principal management
group responsible for the strategic operations and allocation of resources of the
Johnson & Johnson Family of Companies. Johnson & Johnson's operating
companies are organized into three business segments: Consumer, Pharmaceutical
and Medical Devices and Diagnostics. A Group Operating Committee, composed
of managers who represent key operations within the segment, as well as
management in specialized functional departments, oversees and coordinates the
activities of domestic and international companies related to each of the business
segments. However, in line with the principle of decentralized management, senior
management groups at U.S. and international operating companies are each
responsible for their own strategic plans, as well as the day-to-day operations of
those companies, and each international company is, with some exceptions,
managed by citizens of the country where it is located.

Our Company
Our Caring
Our Products
Our Credo Values
Our History

Shareholder Information Exchange

New York Stock Exchange
Stock Quote (JNJ)
$101.13 $0.31
Minimum 20 minutes delayed

Listed Security
JNJ Common Stock

Transfer Agent

Computershare
Independent Accountants
PriceWaterhouseCoopers LLP